Study of SH006 vs Regorafenib for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new treatment called SH006 for advanced liver cancer that has not responded to previous immunotherapy. It compares SH006 to another drug, regorafenib, to see which works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced liver cancer (HCC).
- Your cancer is at stage B or C of the Barcelona Clinic Liver Cancer system and cannot be surgically removed or treated with local therapy.
- You have already tried a drug that blocks immune checkpoints and it did not work.
- Your liver function is relatively good (Child-Pugh score of 7 or less) and you have no history of liver encephalopathy.
- You are between 18 and 75 years old.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (regorafenib) for people with advanced hepatocellular carcinoma (liver cancer) that has gotten worse after or during first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer.
This study tests a combination of three drugs—TUDCA (a bile acid supplement), camrelizumab (an immunotherapy), and regorafenib (a targeted therapy)—for people with advanced liver cancer that has continued to grow after earlier immunotherapy plus Avastin treatment. The goal is to see if this new mix can help stop the cancer from growing.
This trial tests SHR-8068 combined with adebrelimab and bevacizumab in people with advanced, hard-to-treat liver cancer. It aims to see whether this combination can shrink tumors and improve outcomes after standard treatments don’t work or aren’t an option.
This study tests QL1706 together with bevacizumab and/or chemotherapy as an initial (first) treatment for advanced liver cancer. It may help shrink tumors or control the disease when surgery or local treatments aren’t suitable.
This trial tests a new combination of three drugs (SHR-8068, adebrelimab, and bevacizumab) against two standard immunotherapy combinations (sintilimab or atezolizumab plus bevacizumab) for people with advanced liver cancer who haven't had systemic treatment before. The goal is to see if the new combo works better for shrinking or controlling the cancer.
This trial tests a new drug combination called MRG006A for people with advanced liver cancer (hepatocellular carcinoma) that cannot be removed by surgery or treated with local therapies. The goal is to see if it helps shrink tumors or slow cancer growth.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.